Condition 1: Acute Burn. Condition 2: Acute Burn. Condition 3: Acute Burn. Condition 4: Acute Burn. Condition 5: Acute Burn. Condition 6: Acute Burn. Burn of unspecified degree of head, face, and neck, unspecified site Burn of unspecified degree of trunk, unspecified site Burn of unspecified degree of shoulder and upper limb, except wrist and hand, unspecified site Burn of unspecified degree of hand, unspecified site Burn of unspecified degree of unspecified site of lower limb, except ankle
Conditions
Interventions
Intervention 1: Control group: In the first 24 hours of admission, patients receive normal saline solution (Ringer's lactate) and the patient's dose is calculated with the help of the Parkland formula
Sponsors
Bandare-abbas University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Having wounds from 20 to 50% of the total body surface Consent to participate in data collection From the age of 18 to the age of 65 and of both sexes A history of acute burns in the last two days
Exclusion criteria
Exclusion criteria: Medical conditions against propranolol use Head injury History of cardiopulmonary endocrine and peripheral diseases Systolic blood pressure less than 90 Heart rate less than 60 Inhalation damage History of malignancy History of AIDS Complexes related to AIDS and HIV History of IMI (less than the last 6 weeks), tuberculosis, arthritis, cirrhosis, hyperlipidemia, bone or endocrine diseases, autoimmune diseases Long-term use of corticosteroids or non-steroidal anti-inflammatory drugs Renal failure defined as creatinine greater than 3 Liver disease defined as bilirubin more than 3 Anoxic brain damage Patients with asthma and a history of airway narrowing Respiratory burn History of joint or bone disease Peripheral or central nerve damage Diabetes or taking any medication that affects the autonomic system Any type of plastering Skin wound or skin graft Contraindication to the use of propranolol Hypersensitivity to propranolol A history of hyperthyroidism, unless you are using Synthroid or other thyroid hormones Chronic opioid overdose pre-burn Receiving propranolol in the past 6 months Multiple severe allergic reactions Daily use of methylphenidate or similar stimulants Presence of hypoxic brain injury that is not expected to lead to full recovery History of chronic obstructive pulmonary disease and history of medication use including blocking agents (alpha and beta) or other antiarrhythmic drugs and medical conditions requiring glucocorticoid therapy prior to burn injury.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood pressure. Timepoint: At the beginning of the intervention and during the intervention every 3 hours until the end of discharge from the hospital. Method of measurement: Barometer.;Heart rate. Timepoint: At the beginning of the intervention and during the intervention every 3 hours until the end of discharge from the hospital. Method of measurement: patient vital signs monitoring system.;Body temperature. Timepoint: At the beginning of the intervention and during the intervention every 3 hours until the end of discharge from the hospital. Method of measurement: Thermometer.;Blood oxygen. Timepoint: At the beginning of the intervention and during the intervention every 3 hours until the end of discharge from the hospital. Method of measurement: Pulse Oximeter. | — |
Secondary
| Measure | Time frame |
|---|---|
| Hospitalization in ICU. Timepoint: Before starting the intervention and After completing the intervention. Method of measurement: Count by number of days.;The duration of the patient's recovery during the intervention period. Timepoint: Before starting the intervention and After completing the intervention. Method of measurement: check list.;Mortality. Timepoint: Before starting the intervention and After completing the intervention. Method of measurement: Check list.;TNF-alpha. Timepoint: Before starting the intervention and After completing the intervention. Method of measurement: Examination of cytokine TNF-alpha using ELISA kit. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Sadegh Ahmadi Rashti
Bandare-abbas University of Medical Sciences
Outcome results
None listed